J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.

Johnson & Johnson (NYSE:JNJ) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ...

Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in ...

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

The additional analysis confirmed that patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their Myasthenia Gravis Activities of Daily Living (MG-ADL ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics and emerging therapies.

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

March 18, 2025 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD ...

Johnson & Johnson announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label ...

Johnson & Johnson announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press release from Johnson & Johnson. The announcement comes 5 months after the ...